This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
5 Stocks With Recent Price Strength to Maximize Your Gains
by Nalak Das
Investors target stocks that are witnessing a bullish run. Some of the stocks seeing price strength are IMCR, EDAP, BBSI, OSBC and MNSB.
Intra-Cellular's (ITCI) Caplyta Aids Growth, Overdependence a Woe
by Zacks Equity Research
Intra-Cellular Therapeutics (ITCI) currently has only one marketed product in its portfolio, Caplyta, approved for schizophrenia and bipolar disorders. The company is evaluating the candidate in several other indications.
Monopar Therapeutics (MNPR) Up On Soft Tissue Sarcoma Study Data
by Zacks Equity Research
Monopar Therapeutics (MNPR) surges after it reports data from its ongoing phase Ib dose escalation study evaluating camsirubicin for treating soft-tissue sarcoma.
Inhibrx (INBX) Down on Updated Data From Bone Cancer Study
by Zacks Equity Research
Inhibrx (INBX) shares fall after it reports safety and efficacy data from phase I cohorts of a study evaluating its lead candidate INBRX-109 for chondrosarcoma.
Editas (EDIT) Pauses Eye Disease Study on EDIT-101, Stock Down
by Zacks Equity Research
Editas (EDIT) pauses enrollment in the phase I/II BRILLIANCE study evaluating EDIT-101 for treating blindness due to Leber congenital amaurosis 10. Stock falls.
Are Medical Stocks Lagging Immunocore (IMCR) This Year?
by Zacks Equity Research
Here is how Immunocore Holdings PLC Sponsored ADR (IMCR) and Medpace (MEDP) have performed compared to their sector so far this year.
Immunovant (IMVT) Rises More Than 150% in 3 Months: Here's How
by Zacks Equity Research
Immunovant (IMVT) is making good progress with its lead pipeline candidate, batoclimab, which is being developed for treating myasthenia gravis, thyroid eye disease and other autoimmune diseases.
Arcutis (ARQT) Up on Top-Line Data From Atopic Dermatitis Study
by Zacks Equity Research
Arcutis Biotherapeutics (ARQT) reports positive top-line data from a phase III study of its lead candidate, roflumilast cream 0.15%, for treating atopic dermatitis.
What Makes Immunocore Holdings PLC Sponsored ADR (IMCR) a Good Fit for "Trend Investing"
by Zacks Equity Research
If you are looking for stocks that are well positioned to maintain their recent uptrend, Immunocore Holdings PLC Sponsored ADR (IMCR) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.
Why Immunocore (IMCR) Might Surprise This Earnings Season
by Zacks Equity Research
Immunocore (IMCR) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Best Momentum Stocks to Buy for November 3rd
by Zacks Equity Research
PDS, IMCR and USER made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on November 3, 2022.
New Strong Buy Stocks for November 3rd
by Zacks Equity Research
ALX, PDS, IMCR, PXS and CFR have been added to the Zacks Rank #1 (Strong Buy) List on November 3, 2022.
Can Humana (HUM) Sustain Its Earnings Beat Streak in Q3?
by Zacks Equity Research
Humana's (HUM) Q3 results are expected to reflect growing premiums, attributable to its Medicare Advantage and Medicaid businesses. However, elevated marketing costs might have strained its margins.
Wall Street Analysts Predict a 30% Upside in Immunocore Holdings PLC Sponsored ADR (IMCR): Here's What You Should Know
by Zacks Equity Research
The mean of analysts' price targets for Immunocore Holdings PLC Sponsored ADR (IMCR) points to a 29.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Sesen Bio (SESN) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Sesen Bio's (SESN) third-quarter earnings are likely to reflect the cost savings from the company's restructuring plans.
AVEO Oncology (AVEO) to Report Q3 Earnings: Is a Beat in Store?
by Zacks Equity Research
AVEO Oncology's (AVEO) third-quarter earnings is expected to reflect strong Fotivda sales. The company is likely to beat the Zacks Consensus Estimate.
Mind Medicine (MNMD) to Report Q3 Earnings: What's in Store?
by Zacks Equity Research
Mind Medicine MindMed (MNMD) is expected to provide an update on its pipeline candidates in its third-quarter earnings.
Strength Seen in Immunocore Holdings PLC Sponsored ADR (IMCR): Can Its 10.2% Jump Turn into More Strength?
by Zacks Equity Research
Immunocore Holdings PLC Sponsored ADR (IMCR) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
VBI Vaccine (VBIV) Inks Deal With Agenus for Brain Cancer Study
by Zacks Equity Research
VBI Vaccines (VBIV) enters into a partnership with Agenus to conduct a study evaluating the former's VBI-1901 in combination with the latter's balstilimab for primary glioblastoma.
DICE Therapeutics (DICE) Up on Top-Line Data From Psoriasis Study
by Zacks Equity Research
DICE Therapeutics (DICE) reports positive top-line data from a phase I study, evaluating its lead candidate DC-806 for treating psoriasis. Stock up.
Albireo (ALBO) Up on Results From Alagille Syndrome Study
by Zacks Equity Research
Albireo Pharma (ALBO) reports positive top-line data from a late-stage study evaluating Bylvay in Alagille syndrome. The study meets the primary and key secondary endpoint Stock up.
scPharmaceuticals (SCPH) Plunges Despite Furoscix's FDA Approval
by Zacks Equity Research
scPharmaceuticals (SCPH) receives FDA approval for its proprietary heart failure therapy. It also reported a debt refinancing agreement to help with the drug launch.
Wall Street Analysts Believe Immunocore Holdings PLC Sponsored ADR (IMCR) Could Rally 60%: Here's is How to Trade
by Zacks Equity Research
The consensus price target hints at a 60.4% upside potential for Immunocore Holdings PLC Sponsored ADR (IMCR). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Avidity (RNA) Down on Partial Hold of Myotonic Dystrophy Study
by Zacks Equity Research
Avidity Biosciences (RNA) reports FDA-imposed partial hold on enrolling new patients in its phase I/II MARINA study evaluating AOC 1001 in myotonic dystrophy type 1 in adults. Stock down.
Bellerophon (BLPH) Receives FDA Acceptance to Reduce Study Size
by Zacks Equity Research
Bellerophon's (BLPH) proposal to reduce the size of its ongoing phase III REBUILD study of INOpulse in fibrotic Interstitial Lung Disease gets accepted by the FDA. Stock up.